SBME Symposium 2024
Join us and our outstanding community of faculty, trainees, industry and hospital partners, and students as we continue to define the future of health and healthcare at our annual Symposium. • Learn from peers making an impact in the biomedical engineering field. • Discover the latest research.
Events
Calendar
- This event has passed.
Special Seminar: Engineering Bacteria as Living Drug Delivery Systems
February 7 @ 11:00 am - 12:00 pm PST
Speaker: Tetsuhiro Harimoto, PhD (he/him)
Wednesday, Feb 7, 2024
Time: 11:00am-12:00pm Pacific time
Location: LSC 1003 LT3 + online
Zoom: https://ubc.zoom.us/j/62334561670?pwd=SVJISFJISWhIWHU1cmtWVTFmeUVLQT09
Meeting ID: 623 3456 1670
Passcode: 502196
Abstract: Engineered living cells as therapeutic agents are transforming modern medicine. An emerging focus is tumour-colonizing bacteria, where systemically delivered bacteria have been demonstrated to selectively grow within solid tumours. This natural tropism to tumours presents a unique opportunity to engineer bacteria as programmable drug delivery vehicles to regions inaccessible with existing chemo- and immuno-therapeutics. In this talk, I will describe our recent efforts to enhance bacterial cancer therapies through synthetic biology. I will focus on strategies to address several key challenges for clinical translation, including bacterial delivery, therapeutic identification, and off-target effects. Our multidisciplinary approach, spanning from gene circuit design to in vitro and in vivo models, advances bacteria as next-generation drug carriers capable of sensing and responding to diseases within the body.
Bio: Tetsuhiro received his Ph.D. in Biomedical Engineering from Columbia University in 2022. His graduate work in Dr. Tal Danino’s lab focused on the engineering of living microbes as advanced drug delivery vehicles, with a specific focus on tumour-homing bacteria as cancer therapeutics. Currently, Tetsuhiro is an NCI F99/K00 postdoctoral fellow in the Wyss Institute for Biologically Inspired Engineering at Harvard University. Working with Dr. David Mooney, Tetsuhiro is developing engineered living materials as next-generation drug delivery systems. Tetsuhiro was named as one of STAT’s Wunderkinds and recognized in MIT Technology Review’s Innovators Under 35 in 2023.